Is COAG or CTNM more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Contineum Therapeutics N/A -24.73% -23.51%

Does the media favor AGIO or CTNM?

In the previous week, Agios Pharmaceuticals had 18 more articles in the media than Contineum Therapeutics. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 12 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.98 beat Agios Pharmaceuticals' score of 0.37 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Contineum Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTNM or ZLAB?

In the previous week, Contineum Therapeutics had 10 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Contineum Therapeutics and 2 mentions for Zai Lab. Contineum Therapeutics' average media sentiment score of 0.98 beat Zai Lab's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HRMY or CTNM?

In the previous week, Contineum Therapeutics had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 12 mentions for Contineum Therapeutics and 10 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.17 beat Contineum Therapeutics' score of 0.98 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SION or CTNM more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Sionna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -27.31% -25.88% Contineum Therapeutics N/A -24.73% -23.51%

Does the media prefer SION or CTNM?

In the previous week, Contineum Therapeutics had 9 more articles in the media than Sionna Therapeutics. MarketBeat recorded 12 mentions for Contineum Therapeutics and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 1.22 beat Contineum Therapeutics' score of 0.98 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Contineum Therapeutics (CTNM) Competitors

$15.49 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$15.46 -0.03 (-0.19%)

As of 07/31/2026 04:43 PM Eastern

Compare

CTNM vs. COAG, AGIO, ZLAB, HRMY, and SION

Should you buy Contineum Therapeutics stock or one of its competitors? MarketBeat compares Contineum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Contineum Therapeutics include Hemab Therapeutics (COAG), Agios Pharmaceuticals (AGIO), Zai Lab (ZLAB), Harmony Biosciences (HRMY), and Sionna Therapeutics (SION).

How does Contineum Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Contineum Therapeutics (NASDAQ:CTNM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Hemab Therapeutics presently has a consensus price target of $48.00, indicating a potential upside of 0.95%. Contineum Therapeutics has a consensus price target of $20.25, indicating a potential upside of 30.73%. Given Contineum Therapeutics' higher possible upside, analysts clearly believe Contineum Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Hemab Therapeutics has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A
Contineum Therapeutics	$50M	11.58	-$59.98M	-$1.73	N/A

In the previous week, Contineum Therapeutics had 11 more articles in the media than Hemab Therapeutics. MarketBeat recorded 12 mentions for Contineum Therapeutics and 1 mentions for Hemab Therapeutics. Contineum Therapeutics' average media sentiment score of 0.98 beat Hemab Therapeutics' score of -1.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Hemab Therapeutics	Negative
Contineum Therapeutics	Positive

Hemab Therapeutics' return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Contineum Therapeutics	N/A	-24.73%	-23.51%

Summary

Hemab Therapeutics and Contineum Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Contineum Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

In the previous week, Agios Pharmaceuticals had 18 more articles in the media than Contineum Therapeutics. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 12 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.98 beat Agios Pharmaceuticals' score of 0.37 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Contineum Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Contineum Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	33.17	-$412.78M	-$7.01	N/A
Contineum Therapeutics	$50M	11.58	-$59.98M	-$1.73	N/A

Contineum Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Contineum Therapeutics' return on equity of -24.73% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Agios Pharmaceuticals currently has a consensus price target of $40.88, indicating a potential upside of 36.16%. Contineum Therapeutics has a consensus price target of $20.25, indicating a potential upside of 30.73%. Given Agios Pharmaceuticals' higher possible upside, equities research analysts plainly believe Agios Pharmaceuticals is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Contineum Therapeutics beats Agios Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Contineum Therapeutics compare to Zai Lab?

Contineum Therapeutics (NASDAQ:CTNM) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Contineum Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Contineum Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Zai Lab	-39.29%	-24.32%	-15.52%

Contineum Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	11.58	-$59.98M	-$1.73	N/A
Zai Lab	$460.16M	4.52	-$175.54M	-$1.62	N/A

In the previous week, Contineum Therapeutics had 10 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Contineum Therapeutics and 2 mentions for Zai Lab. Contineum Therapeutics' average media sentiment score of 0.98 beat Zai Lab's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.7% of Zai Lab shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Contineum Therapeutics currently has a consensus target price of $20.25, indicating a potential upside of 30.73%. Zai Lab has a consensus target price of $40.00, indicating a potential upside of 118.94%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Zai Lab beats Contineum Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Contineum Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Contineum Therapeutics (NASDAQ:CTNM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Harmony Biosciences has a net margin of 16.20% compared to Contineum Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Harmony Biosciences presently has a consensus target price of $42.63, indicating a potential upside of 20.96%. Contineum Therapeutics has a consensus target price of $20.25, indicating a potential upside of 30.73%. Given Contineum Therapeutics' higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Contineum Therapeutics had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 12 mentions for Contineum Therapeutics and 10 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.17 beat Contineum Therapeutics' score of 0.98 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.2% of Harmony Biosciences shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Harmony Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$899.11M	2.27	$158.69M	$2.48	14.21
Contineum Therapeutics	$50M	11.58	-$59.98M	-$1.73	N/A

Summary

Harmony Biosciences beats Contineum Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Contineum Therapeutics compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Contineum Therapeutics (NASDAQ:CTNM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Contineum Therapeutics has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Contineum Therapeutics	$50M	11.58	-$59.98M	-$1.73	N/A

Sionna Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Sionna Therapeutics presently has a consensus target price of $53.22, indicating a potential upside of 12.93%. Contineum Therapeutics has a consensus target price of $20.25, indicating a potential upside of 30.73%. Given Contineum Therapeutics' higher possible upside, analysts clearly believe Contineum Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Contineum Therapeutics' return on equity of -24.73% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Contineum Therapeutics	N/A	-24.73%	-23.51%

In the previous week, Contineum Therapeutics had 9 more articles in the media than Sionna Therapeutics. MarketBeat recorded 12 mentions for Contineum Therapeutics and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 1.22 beat Contineum Therapeutics' score of 0.98 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Contineum Therapeutics beats Sionna Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTNM vs. The Competition

Export

Metric	Contineum Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$579.17M	$11.71B	$6.86B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-8.95	799.05	282.30	24.66
Price / Sales	11.58	751.29	564.98	76.51
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	2.22	10.36	10.92	6.07
Net Income	-$59.98M	$2.82B	$3.49B	$347.99M
7 Day Performance	11.76%	-0.13%	-0.64%	-0.44%
1 Month Performance	2.58%	-3.99%	-5.24%	-4.81%
1 Year Performance	159.90%	156.16%	61.98%	18.61%

Contineum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTNM Contineum Therapeutics	1.9089 of 5 stars	$15.49 flat	$20.25 +30.7%	+159.9%	$579.17M	$50M	N/A	31	News Coverage Earnings Report Upcoming Earnings Analyst Forecast Gap Up
COAG Hemab Therapeutics	1.629 of 5 stars	$45.27 -4.2%	$48.00 +6.0%	N/A	$2.11B	N/A	N/A	72	Negative News
AGIO Agios Pharmaceuticals	2.7571 of 5 stars	$35.23 -2.1%	$40.00 +13.5%	-14.2%	$2.10B	$66.05M	N/A	390	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Down
ZLAB Zai Lab	2.5559 of 5 stars	$18.27 -1.9%	$40.00 +119.0%	-50.4%	$2.08B	$460.16M	N/A	1,784	Upcoming Earnings
HRMY Harmony Biosciences	4.6532 of 5 stars	$35.86 +0.2%	$42.50 +18.5%	+2.4%	$2.08B	$868.45M	14.47	200	Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTNM) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contineum Therapeutics (CTNM) Competitors

CTNM vs. COAG, AGIO, ZLAB, HRMY, and SION

How does Contineum Therapeutics compare to Hemab Therapeutics?

Summary

How does Contineum Therapeutics compare to Agios Pharmaceuticals?

Summary

How does Contineum Therapeutics compare to Zai Lab?

Summary

How does Contineum Therapeutics compare to Harmony Biosciences?

Summary

How does Contineum Therapeutics compare to Sionna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Contineum Therapeutics (CTNM) Competitors

CTNM vs. COAG, AGIO, ZLAB, HRMY, and SION

How does Contineum Therapeutics compare to Hemab Therapeutics?

Do analysts prefer COAG or CTNM?

Which has better valuation and earnings, COAG or CTNM?

Does the media favor COAG or CTNM?

Is COAG or CTNM more profitable?

Summary

How does Contineum Therapeutics compare to Agios Pharmaceuticals?

Does the media favor AGIO or CTNM?

Which has more volatility and risk, AGIO or CTNM?

Which has higher earnings & valuation, AGIO or CTNM?

Is AGIO or CTNM more profitable?

Do analysts prefer AGIO or CTNM?

Summary

How does Contineum Therapeutics compare to Zai Lab?

Which has more risk and volatility, CTNM or ZLAB?

Is CTNM or ZLAB more profitable?

Which has better valuation & earnings, CTNM or ZLAB?

Does the media favor CTNM or ZLAB?

Do institutionals & insiders hold more shares of CTNM or ZLAB?

Do analysts rate CTNM or ZLAB?

Summary

How does Contineum Therapeutics compare to Harmony Biosciences?

Is HRMY or CTNM more profitable?

Do analysts recommend HRMY or CTNM?

Does the media refer more to HRMY or CTNM?

Do insiders and institutionals believe in HRMY or CTNM?

Which has more risk and volatility, HRMY or CTNM?

Which has stronger valuation & earnings, HRMY or CTNM?

Summary

How does Contineum Therapeutics compare to Sionna Therapeutics?

Which has higher earnings & valuation, SION or CTNM?

Which has more volatility and risk, SION or CTNM?

Do analysts prefer SION or CTNM?

Is SION or CTNM more profitable?

Does the media prefer SION or CTNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools